---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-004756"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:27:16.779768+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CERO Therapeutics gets Nasdaq Panel extension to April 22, 2025 for listing compliance

## Summary
- Nasdaq Panel grants extension to regain compliance with $50M MVLS, $15M MVPHS, and $1.00 bid price requirements.
- Company completed 100:1 reverse stock split on Jan 8, 2025; stock closed above $1.00 since then.
- Must apply to transfer to Nasdaq Capital Market by Jan 22, 2025 and meet $2.5M stockholders' equity.
- Equity raised from committed facility and warrant exercises since Sep 30, 2024; additional capital raising planned.
- Company cannot assure success in raising capital or meeting equity requirement by extension date.

## SEC filing metadata
- accession: 0001213900-25-004756
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025004756/0001213900-25-004756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025004756/ea0228123-8k_cerotherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-004756
- JSON: https://secwatch.observer/filing/0001213900-25-004756.json
- Plain text: https://secwatch.observer/filing/0001213900-25-004756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.